Buprenorphine for Chronic Pain Management in Patients with Opioid Use Disorder

Introduction to Buprenorphine Therapy

Buprenorphine can and should be used for chronic pain management, particularly in patients with a history of opioid use disorder, as it provides effective analgesia while maintaining addiction treatment and offering superior safety compared to full opioid agonists, according to the Infectious Diseases Society of America 1, 2
The American Academy of HIV Medicine recommends buprenorphine as a first-line treatment for chronic pain in patients with opioid use disorder due to its unique ability to address both conditions simultaneously 1, 3

Buprenorphine demonstrates a ceiling effect on respiratory depression, making it significantly safer than hydromorphone, fentanyl, or other full agonists—a critical consideration given the overdose risks in this vulnerable population, as noted by the Clinical Infectious Diseases journal 4, 5
Systematic reviews confirm comparable pain relief to morphine and fentanyl but with fewer adverse events, highlighting the medication's safety profile, according to the Clinical Infectious Diseases journal 6, 7

The Infectious Diseases Society of America suggests increasing the existing buprenorphine dose in divided doses as the first-line strategy for managing chronic pain in patients already on buprenorphine for opioid use disorder 1, 2
Dosing ranges of 4-16 mg divided into 8-hour doses have demonstrated benefit in patients with chronic noncancer pain, with improved functioning and mood, as reported by the Clinical Infectious Diseases journal 1, 8

If maximal buprenorphine doses are reached without adequate analgesia, the American Academy of HIV Medicine recommends adding a long-acting potent opioid such as fentanyl, morphine, or hydromorphone, while closely monitoring the patient 1, 2
Buprenorphine's high binding affinity for the μ-opioid receptor may prevent lower doses of other opioids from accessing receptors, so higher doses of the additional opioid may be required, according to the Clinical Infectious Diseases journal 1, 9

All patients must be screened for depression before initiating long-term opioid therapy, as mental health significantly impacts pain outcomes and substance use risk, as recommended by the Infectious Diseases Society of America 6, 4
The two-question screen and PHQ-9 can be used for further assessment, with scores ≥10 requiring psychiatric referral, according to the Clinical Infectious Diseases journal 6, 3

Switching patients who are receiving high‑dose full‑mu opioid agonists for chronic pain to extended‑release buprenorphine leads to substantial improvements in pain control and quality‑of‑life measures, based on small retrospective cohort studies. Evidence level: low‑quality observational data. 10
In individuals with opioid use disorder, treatment with extended‑release buprenorphine reduces the risk of fatal overdose by approximately three‑fold compared with no medication‑assisted therapy. Evidence level: low‑quality observational data. 10

Complex Persistent Opioid Dependence – Patients who remain on high opioid doses, experience poor analgesia and functional impairment, and whose symptoms worsen when opioid doses are either reduced or increased (yet do not meet full criteria for opioid use disorder) are specifically indicated for a buprenorphine trial. Evidence level: low‑quality observational data. 10
The U.S. Department of Health and Human Services clinical guide recommends initiating a buprenorphine trial in persons who fail to achieve adequate pain relief or functional improvement with high‑dose opioid regimens and who respond poorly to taper attempts. Evidence level: guideline recommendation based on expert consensus. 10

Buprenorphine’s partial‑agonist profile and ceiling effect on respiratory depression make it markedly safer than full‑opioid agonists; patients on extended‑release buprenorphine exhibit markedly lower rates of respiratory compromise in pain‑management case series. Evidence level: low‑quality case series (cited within the same source). 10
Because buprenorphine occupies μ‑opioid receptors with high affinity, supplemental rescue opioids (e.g., fentanyl, morphine) often require higher-than‑usual doses to achieve analgesia when added to a maximal buprenorphine regimen. Evidence level: low‑quality observational data. 10
Treatment with buprenorphine is associated with a reduced propensity for dose escalation and a lower urge for patients on high‑dose opioids to seek larger opioid quantities. Evidence level: low‑quality observational data. 10

Deterioration in pain or function after opioid reduction should not automatically be attributed to opioid dependence; underlying pain pathology may become unmasked, underscoring the need for comprehensive reassessment. Evidence level: low‑quality observational data. 10